FLT3 and acute myeloid leukemia: The Mayo genetic risk model was validated by using an MD Anderson Cancer Center cohort (MDACC) of 117 ND‐AML patients (median age 73; years, 61% males) receiving Ven‐HMA; 53 (45%) of patients harbored ELN 2022 adverse karyotype; 3 (3%) with KMT2Ar; mutations involved TP53 (35%), NPM1 (22%), IDH2 (15%), RUNX1 (12%), IDH1 (10%), FLT3‐ITD (3%), DDX41 (3%).